- Investing Ideas
- Swiss Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Swiss Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Results
17
Strong Balance Sheet Stocks: companies with a Health score of at least 4, ordered by Health score.
17 companies
Sandoz Group
Market Cap: CHF 26.8b
Develops, manufactures, and markets generic and biosimilars worldwide.
SDZ
CHF 61.94
7D
-2.4%
1Y
67.1%
Bachem Holding
Market Cap: CHF 4.5b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 60.35
7D
8.5%
1Y
12.6%
Kuros Biosciences
Market Cap: CHF 986.4m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 25.18
7D
-4.5%
1Y
28.6%
Lonza Group
Market Cap: CHF 33.8b
Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
LONN
CHF 481.00
7D
-4.6%
1Y
-12.3%
Basilea Pharmaceutica
Market Cap: CHF 636.7m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 51.80
7D
-0.4%
1Y
9.4%
Molecular Partners
Market Cap: CHF 125.1m
A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
MOLN
CHF 3.35
7D
-14.2%
1Y
-9.3%
SKAN Group
Market Cap: CHF 1.1b
Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.
SKAN
CHF 48.55
7D
-1.7%
1Y
-33.2%
Tecan Group
Market Cap: CHF 1.5b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 121.50
7D
-4.9%
1Y
-30.7%
Dottikon ES Holding
Market Cap: CHF 4.8b
Manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical maceutic industries in Europe, Switzerland, the United States, and Asia.
DESN
CHF 344.00
7D
2.7%
1Y
76.6%
Addex Therapeutics
Market Cap: CHF 5.2m
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland.
ADXN
CHF 0.045
7D
-10.0%
1Y
-19.6%
BioVersys
Market Cap: CHF 158.5m
A clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria.
BIOV
CHF 27.10
7D
5.9%
1Y
-24.1%
PolyPeptide Group
Market Cap: CHF 801.7m
Operates as a contract development and manufacturing company in Europe, the United States, and India.
PPGN
CHF 24.30
7D
2.3%
1Y
30.9%
Roche Holding
Market Cap: CHF 256.1b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROG
CHF 320.70
7D
-6.0%
1Y
4.9%
Galderma Group
Market Cap: CHF 33.7b
Operates as a dermatology company worldwide.
GALD
CHF 143.80
7D
-7.8%
1Y
59.5%
Cosmo Pharmaceuticals
Market Cap: CHF 1.4b
A life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.
COPN
CHF 87.00
7D
-19.0%
1Y
60.5%
Siegfried Holding
Market Cap: CHF 3.4b
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.
SFZN
CHF 78.30
7D
-1.0%
1Y
-12.5%
Newron Pharmaceuticals
Market Cap: CHF 341.3m
A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.
NWRN
CHF 16.44
7D
-6.8%
1Y
95.2%